Granite Point Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Granite Point Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-58,000	Closed	-$761K	–	120
2019 Q1	$761K	Sell	58,000 -17,000	-23%	-$248K	0.07%	75
2018 Q4	$1.08M	Hold	75,000	–	–	0.22%	52
2018 Q3	$1.34M	Buy	+75,000	New	+$1.3M	0.09%	72

Other funds holding OPNT

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Granite Point Capital Management's OPNT Position: Q2 2019 in Review

Granite Point Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2019, closing a stake of 58,000 shares — an estimated $761K sold.

Granite Point Capital Management first reported a position in OPNT in Q3 2018 and held it in 3 quarters. The position peaked at $1.34M in Q3 2018. 15 funds tracked by Wall St. Rank hold OPNT as of Q2 2019.

Granite Point Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Granite Point Capital Management sold 58,000 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $761K.
Granite Point Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
Granite Point Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1.34M in Q3 2018.
15 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Granite Point Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.